Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker - Test2 - elhamkhani - TriplyDB

Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker

Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker

http://www.wikidata.org/entity/Q27681964

about

Delineation of Polypharmacology across the Human Structural Kinome Using a Functional Site Interaction Fingerprint Approach Spotlight on afatinib and its potential in the treatment of squamous cell lung cancer: the evidence so far Molecularly targeted therapy for the treatment of head and neck cancer: a review of the ErbB family inhibitors Targeting RTK Signaling Pathways in Cancer Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer Profile of neratinib and its potential in the treatment of breast cancer Human epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancer Selective Inhibition of the Immunoproteasome by Structure-Based Targeting of a Non-catalytic Cysteine Afatinib, an Irreversible EGFR Family Inhibitor, Shows Activity Toward Pancreatic Cancer Cells, Alone and in Combination with Radiotherapy, Independent of KRAS Status.New developments in the management of non-small-cell lung cancer, focus on rociletinib: what went wrong?Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence Pharmacogenomics of EGFR-targeted therapies in non-small cell lung cancer: EGFR and beyond Afatinib for the treatment of metastatic non-small cell lung cancer NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer Drug resistance missense mutations in cancer are subject to evolutionary constraints Pathway-Based Genomics Prediction using Generalized Elastic Net Covalent Modifiers: A Chemical Perspective on the Reactivity of α,β-Unsaturated Carbonyls with Thiols via Hetero-Michael Addition Reactions Potential strategies for increasing drug-discovery productivity.Phase I trial of afatinib plus vinorelbine in Japanese patients with advanced solid tumors, including breast cancer.A phase I study of volasertib combined with afatinib, in advanced solid tumors.Afatinib radiosensitizes head and neck squamous cell carcinoma cells by targeting cancer stem cells.A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer.Afatinib ameliorates osteoclast differentiation and function through downregulation of RANK signaling pathways.Influence of Renal Impairment on the Pharmacokinetics of Afatinib: An Open-Label, Single-Dose Study.New developments in the treatment of advanced squamous cell lung cancer: focus on afatinib.Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy Blocking autophagy improves the anti-tumor activity of afatinib in lung adenocarcinoma with activating EGFR mutations in vitro and in vivo.Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment.Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidence Therapeutic options for HER-2 positive breast cancer: Perspectives and future directions A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors.A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations Small-molecule inhibitors of the receptor tyrosine kinases: promising tools for targeted cancer therapies Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer.Experience with afatinib in patients with non-small cell lung cancer progressing after clinical benefit from gefitinib and erlotinib.Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors.Effect of combined irradiation and EGFR/Erb-B inhibition with BIBW 2992 on proliferation and tumour cure in cell lines and xenografts.Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease.Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized c

P2860

Q24672143-0C5848E0-E865-4B4A-9AE0-E2430FB32213 Q26745776-1378EA22-65F9-4BAB-8770-458B96A1CCBD Q26750719-A6D4585C-0173-45B7-96A3-2E22E3177DCC Q26781278-2E21F243-52AD-4E2B-96F5-F7C037C8F4C3 Q26824799-BEBB3C8E-7BE1-4B63-9297-6C42577793C2 Q27012540-E487F494-47F5-4382-9744-0C653DEEA8B1 Q27025863-953A239D-346B-439B-B5FE-81D4342AEA3D Q27702605-9C6BD967-0404-407C-BFDB-3DDCFAD339AA Q27853292-7F9BB397-B38E-4D96-A715-2B31C610625E Q28075511-7A7CD13B-944F-46CF-8EA8-379CC49A2EC9 Q28079320-D0217379-3E9A-43EC-AA4C-688FE816D723 Q28080730-87A86271-1F9C-4812-8959-F2B24A31EC59 Q28082181-1B4070D3-B21F-4BF4-B2EB-FC42DAA87E12 Q28259999-1A6A6344-32C0-431B-86A9-20938E842F69 Q28537830-F0E0DD85-EB9E-4C94-8919-4A3D6A606AF5 Q28550614-3008F01C-7C30-4D6E-A595-7AB17B673827 Q29248430-339868AB-EA26-4820-89D8-B84626FEB68C Q31154360-12523E5F-AF46-416B-ADFE-1689B8104602 Q33425039-A002AB6E-9F49-4B13-8CB3-8F0FEEC95C08 Q33425698-78C16035-98A5-44D0-A172-C2F3A2281FAE Q33591405-342EF890-83BF-4045-949E-2DD437B9D5ED Q33605906-BC1B4055-C63B-4DE5-A61D-A49B7FF68840 Q33649260-B82FDCFD-667C-4493-9EA7-8E932A8AA767 Q33653707-D2CF6304-5DDA-4EFA-BC0D-6C29DC203D7E Q33704088-C58EB4EE-B50D-409C-9D8F-332DB2FFBBB5 Q33839177-D3A98EEB-FBCB-40E8-A9AF-74A5C3E620E1 Q33870539-93C53A0F-CC04-4FB8-BA36-2B0C66C052CE Q33954583-DD46984A-DDFC-4E19-B281-368040D6C5F5 Q34011705-5FDCB96F-AEDE-466B-87FD-9B39DA5B8C39 Q34023704-BA601308-4628-4F75-9602-9CFDD448DCA2 Q34067085-B1A7F961-F5DD-4DCD-B00A-9C3CB0D6B2DA Q34083131-37D4FCBA-8693-491E-8950-9BFFB1C316AD Q34135471-7FE107EC-C8F5-498E-9F33-01B64FE58229 Q34158454-B0D3F8A6-19BD-440D-B4E9-9B6A607566BF Q34260686-083823C0-6DDE-42CF-A2E3-C393ECFEA57B Q34359274-EB884124-85ED-4EA6-84F1-5E7C27A3DACB Q34525925-8FEACE4C-3FFC-4867-B517-836976C53C8E Q34740289-4D19993F-2295-4546-A910-9505D413574D Q34772704-50E1F2D3-5E6E-4A0D-9CBB-6AE418904EE1 Q34896542-E6474E89-63BC-496C-ADD4-3E3F855FF1FB

P2860

Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker

http://www.wikidata.org/entity/Q27681964

description

2012 nî lūn-bûn

@nan

2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Target binding properties and ...... reversible ErbB family blocker

@ast

Target binding properties and ...... reversible ErbB family blocker

@en

Target binding properties and ...... reversible ErbB family blocker

@nl

type

label

Target binding properties and ...... reversible ErbB family blocker

@ast

Target binding properties and ...... reversible ErbB family blocker

@en

Target binding properties and ...... reversible ErbB family blocker

@nl

prefLabel

Target binding properties and ...... reversible ErbB family blocker

@ast

Target binding properties and ...... reversible ErbB family blocker

@en

Target binding properties and ...... reversible ErbB family blocker

@nl

P1433

Q27681964-D39C6C3E-D7C5-4B64-AA04-D92A43C6EFD1

P1476

Q27681964-F5EE992D-752E-44E6-977B-D6D568BC6639

P2093

Q27681964-33D82CB1-3F21-4098-8CF3-69488D152A0C

Q27681964-4F8A1D4B-D337-4C40-9E94-939166900333

Q27681964-67BBD4BA-C764-4783-BD26-A4E5A3431A07

Q27681964-81A07D48-2042-447C-8E0B-011B994E7D06

Q27681964-A5C5EE55-F4E9-42C0-AD66-4E4499262DBB

Q27681964-A9B647B1-3514-4210-B8A4-CFE7D202804D

Q27681964-D28B5AC0-1B0F-48DC-9DA4-AB996A5D7E78

Q27681964-DA4AEDCF-2B2B-4EDC-9D9D-93C19CD18EC7

Q27681964-E0080420-ABD8-4EF0-A722-3F1948CBDE5E

P304

Q27681964-60F50346-791D-4535-9602-CFFDF9BF2A77

P31

Q27681964-440AF41A-509E-4E37-A24A-52FD13D55F82

P3181

Q27681964-1E0FE738-8E72-488B-85DF-F8279A31E78A

P356

Q27681964-A7082A61-64ED-43ED-9088-E147EDEB6255

P407

Q27681964-43173D8A-A7F9-425A-BDEF-12531B31D7F8

P433

Q27681964-6E1753E5-6977-4F86-8DF4-D1EAEFFA24FC

P478

Q27681964-183727AA-5196-42E4-BC37-2C17DABB55C7

P50

Q27681964-67854305-7F4F-4366-A35D-4CF1B97A37AC

P577

Q27681964-7F6BC2BB-CF5F-4EB0-AB81-DDF920F50D0F

P5875

Q27681964-8568558B-260D-445B-99FB-9016A50767D2

P698

Q27681964-229F8DBC-5BA5-4A64-B270-BD0587612B9E

P921

Q27681964-9629C4EE-E507-4495-AFA1-9938FF0D92DE

P3181

P356

JPET.112.197756

P1433

Journal of Pharmacology and Experimental Therapeutics

P1476

Target binding properties and ...... reversible ErbB family blocker

@en

P2093

Andreas Zoephel

http://www.w3.org/2001/XMLSchema#string

Christian Klein

http://www.w3.org/2001/XMLSchema#string

Eric Haaksma

http://www.w3.org/2001/XMLSchema#string

Flavio Solca

http://www.w3.org/2001/XMLSchema#string

Frank Himmelsbach

http://www.w3.org/2001/XMLSchema#string

Gerd Bader

http://www.w3.org/2001/XMLSchema#string

Goeran Dahl

http://www.w3.org/2001/XMLSchema#string

Guenther R Adolf

http://www.w3.org/2001/XMLSchema#string

Oliver Kraemer

http://www.w3.org/2001/XMLSchema#string

P304

342-50

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1345407

http://www.w3.org/2001/XMLSchema#string

P356

10.1124/JPET.112.197756

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

343

http://www.w3.org/2001/XMLSchema#string

P50

Michael Sanderson

P577

2012-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230659032

http://www.w3.org/2001/XMLSchema#string

P698

22888144

http://www.w3.org/2001/XMLSchema#string

P921